Abstract 8378: Novel System for the Molecular Imaging of Atherosclerotic Plaque with 68Ga-DOTA-ApoA-I Mimetic Peptide (-FAMP)
Cardiovascular disease is the leading cause of death, and atherosclerosis is a chronic, progressive disease with a long asymptomatic phase. Currently, most diagnostic modalities for atherosclerosis imaging can not provide information on the biology and metabolism of plaque, which could help to identify the stage of the disease. PET has the potential to provide information on the extent and activity of atherosclerotic plaque. We have previously described FAMP, a novel apoA-I mimetic 24-amino acid peptide, which may be able to remove cholesterol via specific ATP-binding cassette transporter A1. In this study, we investigated the potential of FAMP to image developing plaque lesions in vivo. FAMP was modified with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and radiolabeled with 68Ga for noninvasive PET in a familial hypercholesterolemic rabbit (WHHL) with atherosclerotic lesions in the presence or absence of aortic stenting. The uptake of 68Ga-DOTA-FAMP in the atherosclerotic region in WHHL rabbit was visible on small-animal PET images. Aortic atherosclerotic plaque showed a high uptake of 68Ga-DOTA-FAMP in WHHL rabbit (Fig.B), but not in normal (JW) (Fig.A) rabbit in both in vivo and in vitro imaging. Furthermore, 68Ga-DOTA-FAMP also showed strong uptake in aortic-stenting lesion in Planar Positron Imaging System (Fig.C). In conclusion, we demonstrated that 68Ga-DOTA-FAMP is a promising candidate tracer for PET imaging of atherosclerotic plaque. Detection of these plaques which are prone to rupture could be clinically important for the prevention of cardiac events.
- © 2011 by American Heart Association, Inc.